MedTrace Logo

Carbon-11 Labeled Sarcosine in Prostate Cancer

NCT02462447 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2017-11-09

No results posted yet for this study

Summary

Men with and without prostate cancer will have a PET/CT scan that measures the level of the amino acid sarcosine. PET is a scanning method that uses short lived radioactivity.

Conditions

Interventions

DRUG

11C-sarcosine

Radiotracer injection for PET/CT scan

DRUG

11C-choline

Radiotracer injection for PET/CT scan

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Michigan

    lead OTHER

Principal Investigators

  • Morand R Piert, MD · University of Michigan Hospital

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2017-02-08
Completion
2017-02-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462447 on ClinicalTrials.gov